Truist Securities Assumes Perspective Therapeutics at Buy, Raises Price Target to $12

Benzinga · 11/24/2025 18:15
Truist Securities analyst Gregory Renza assumes Perspective Therapeutics (AMEX:CATX) with a Buy rating and raises Price Target to $12.